US Pharm. 2016;41(7):12.
Boston, MA—To address widespread concerns about testosterone therapy (TT) for testosterone deficiency (TD), international experts at a consensus conference developed a set of resolutions and conclusions for physicians and patients. After examining the best available scientific evidence, the participants agreed unanimously that TD is a clinically significant condition that may benefit from treatment, with or without an identified underlying origin; that TD is a global public-health concern; and that TT for men with TD is effective, rational, and evidence-based and there is no scientific basis for age-specific recommendations against TT use in adult males. It was also resolved unanimously that evidence does not support an increased risk of cardiovascular events or of prostate cancer with TT use.
To comment on this article, contact rdavidson@uspharmacist.com.
